Hanmi Pharmaceutical Stock Resilient Despite Profit Dip: Key Insight Hanmi Pharmaceutical stock is discounted by governance and K-bio sentiment, but earnings remain resilient with net income up 6.8% YoY; analysts see Buy with 51% upside to the 624,615 won average target. 2026년 07월 09일 English
Hanmi Pharmaceutical Stock Pops on GLP 2 News – What Earnings Show Hanmi Pharmaceutical shares rallied on Eli Lilly tech transfer headlines, but latest results show flat revenue and falling operating profit (-9.1% YoY). Bulls cite retained Korea rights and net profit stability; bears warn margins may not recover fast enough to justify the premium valuation. 2026년 06월 05일 English
